Federico A. Zuckermann

For over three decades, Dr. Zuckermann has investigated the immune response of swine to major porcine viruses including the PRRS virus. He is the inventor of seven patents and has authored over 80 scientific publications. In 2010, Dr. Zuckermann founded Aptimmune Biologics, Inc. to commercialize vaccine technologies he developed at the University of Illinois Urbana-Champaign, namely a novel porcine macrophage cell line termed ZMAC and a naturally non-virulent strain of PRRS virus. He is past-President of the American Association of Veterinary Immunologists; received numerous research awards; and over $3,000,000 in federal and private research funding. He has consulted or performed research for companies including Boehringer Ingelheim, Pfizer, Bayer Animal Health, Abbott Nutrition, and United Animal Health. Dr. Zuckermann earned a DVM equivalent degree with honors from the National Autonomous University of Mexico, and a Ph.D. in Immunology from the University of Texas Southwestern Graduate School of Biomedical Sciences. After a postdoctoral fellowship at Vanderbilt University. He joined UIUC in 1989, where he holds the position of Professor of Immunology.